Last reviewed · How we verify
NCT05451615
Efficacy and Safety of Abatacept Combined With JAK Inhibitor for Refractory Rheumatoid Arthritis
Phase 3 trial testing Janus Kinase Inhibitor in Abatacept in 90 participants. Status unknown.
30 June 2023
Quick facts
| Lead sponsor | Zhejiang Provincial People's Hospital |
|---|---|
| Phase | Phase 3 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | single group |
| Masking | none |
| Primary purpose | treatment |
| Enrollment | 90 |
| Start date | 30 September 2022 |
| Primary completion | 30 June 2023 |
| Estimated completion | 30 June 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Janus Kinase Inhibitor — full drug profile →
- Abatacept (abatacept) — full drug profile →
Conditions studied
- Abatacept — all drugs for Abatacept →
- Treatment Compliance — all drugs for Treatment Compliance →
- Rheumatoid Arthritis — all drugs for Rheumatoid Arthritis →
Sponsor
Zhejiang Provincial People's Hospital
Who can join
Eligibility, any sex, with Abatacept or Treatment Compliance. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The aim of this study is to observe the clinical efficacy and safety of abatacept combined with JAK inhibitor in the treatment of D2TRA patients
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05451615
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other trials of Janus Kinase Inhibitor
Trials testing the same drug.
- NCT06660329 — Efficacy and Safety of Tofacitinib in Refractory Blau Syndrome · Phase 4 · enrolling by invitation
- NCT06561256 — JAK Inhibitors' Efficacy in Bullous Pemphigoid · completed
- NCT04576000 — Identification of Biomarkers of Janus Kinase Inhibitor Therapy in Patients With Ulcerative Colitis · terminated
Other Zhejiang Provincial People's Hospital trials
Trials by the same sponsor.
- NCT07491016 — Efficacy and Safety of Telitacicept Combined With Baricitinib for Refractory Rheumatoid Arthritis · recruiting
- NCT07212634 — Cerebellar Transcranial Direct Current Stimulation for Dysphagia After Supratentorial Stroke · NA · not yet recruiting
- NCT07312422 — LDRT Combined With Pucotenlimab and Standard Therapy for Advanced Pancreatic Cancer: A Single-Arm Study · Phase 1, PHASE2 · recruiting
- NCT06975644 — Evaluating Bemotuzumab to Improve the Efficacy of Neoadjuvant Chemotherapy for Triple-Negative Breast Cancer (TNBC) · NA · not yet recruiting
- NCT07068542 — Sacituzumab Tirumotecan Combined With Immunotherapy in Advanced Thyroid Cancer · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05451615 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Zhejiang Provincial People's Hospital
- Last refreshed: 23 September 2022
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05451615.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing